Nov 28, 2023 / 04:00PM GMT
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research Analyst
Okay. Good morning. Thanks, everyone, for joining us at the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Alkermes and joining us the CEO, Richard Pops. Delighted to have you with us. And lots to talk about. So I know everyone wants to talk about our favorite topic, orexin agonist 2680. I am not going to start with that; however, we'll start with a high-level question, if that's okay. Since you completed the separation of the oncology business.
Questions and Answers:
David A. Amsellem - Piper Sandler & Co., Research Division - MD & Senior Research AnalystI'm particularly interested in now, how are you thinking about the neuroscience business, the stand-alone Neuroscience business, particularly the cost structure, your margins and, ultimately, your strategic vision for that business over the long term.
Richard F. Pops - Alkermes plc - Chairman & CEO